参松养心胶囊治疗慢性心力衰竭合并室性心律失常的研究进展

摘要

慢性心力衰竭(CHF)并发室性心律失常(VA)是心脏性猝死(SCD)的主要原因.目前治疗CHF合并VA的经典药物为Ⅱ类抗心律失常β受体阻滞剂及Ⅲ类抗心律失常药物胺碘酮,然而许多抗心律失常药物都有致心律失常作用,中成药参松养心胶囊通过对心肌细胞多种离子通道的作用,对Kv1.4△N通道的峰电流的抑制作用及调节心脏自主神经系统、增加心肌组织Na+-K+-ATP酶的活性、抑制心肌重构、改善心脏传导功能等作用,发挥对慢性心力衰竭合并室性心律失常的治疗作用.文章对其治疗CHF合并VA的研究进展进行综述.%There are various reasons lead to heart failure, ventricular arrhythmia are more common,.CHF concurrent ventricular arrhythmia (VA) is the main cause of cardiac sudden death (SCD).Though the classical drus for CHF combined VA are Ⅱ anti-arrhythmic beta-blockers and Ⅲanti-arrhythmic drug such as amiodarone.However,all the anti-arrhythmic drugs have lead to arrhythmia.And the Shensongyangxin capsule has the characteristic of traditional Chinese medicine, play for the treatment of chronic heart failure with ventricular arrhythmia through various mechanism,such as, the myocardial cells of ion channel, the Kv1.4 delta N channel inhibition of peak current and regulate cardiac autonomic nervous system, increase the myocardial tissue Na+-K+ atpase activity and inhibition of myocardial remodeling, improvement the action such as cardiac conduction function etal.The paper reviews there search progress of Chronic heart failure with ventricular arrhythmia of Shensongyangxin capsules.